GIL 2026 | 2026第二十届沙利文峰会圆满闭幕｜锚定创新爆发期，共塑转型增长新未来

8月5日，由弗若斯特沙利文（Frost & Sullivan，简称：“沙利文”）主办，头豹协办的2026第二十届沙利文全球增长、科创与领导力峰会暨第五届新投资大会（以下简称“2026沙利文峰会”或“大会”）在上海静安香格里拉大酒店圆满闭幕。大会集结海内外重磅嘉宾、超150场演讲/圆桌，现场专业观众规模超5,000人。

On August 5, the 20th Frost & Sullivan Global Growth, Innovation and Leadership (GIL) Summit and the 5th New Investment Event (the "2026 Frost & Sullivan Summit" or the "Summit"), hosted by Frost & Sullivan and co-organized by LeadLeo, successfully concluded at Jing An Shangri-La, Shanghai. The Summit gathered distinguished speakers from China and abroad, featuring more than 150 keynotes and panel discussions, with over 5,000 professional attendees on site.

本届大会以“锚定创新爆发期，共塑转型增长新未来”为主题，由中国广告协会、中国上市公司协会、上海现代服务业联合会、上海信息服务业行业协会、上海长三角现代产业发展促进会、上海市咨询业行业协会作为支持单位，汇聚全球产业界、学术界、投资界的智慧与力量，共同探讨新时代下中国经济的新增长点、新市场、新赛道。大会为期2天，由一场开幕式、十大分论坛及多场主题活动构成，分别围绕AI进阶与飞跃、半导体和AI基础设施、新智生产力、生命科学新投资、合成生物与生物制造、新消费及消费出海、人才教育、上市公司高质量发展等全科创产业链核心赛道等热门议题进行深入探讨。

Themed "Anchoring the Innovation Explosion, Shaping New Future of Transformational Growth", and supported by China Advertising Association, China Association for Public Companies, Shanghai Federation of Modern Service Industry, Shanghai Information Service Industry Association, Shanghai Yangtze River Delta Modern Industry Development Promotion Association, and Shanghai Consulting Industry Association, the Summit brought together the insights and expertise of the global industry, academia and investment communities to explore new growth drivers, new markets and new tracks for China's economy in the new era. The two-day Summit consisted of one opening ceremony, ten sub-forums and multiple themed events, covering hot topics across the entire sci-tech innovation value chain, including AI advancement, semiconductors and AI infrastructure, new intelligence productivity, life science new investment, synthetic biology and biomanufacturing, new consumption and global expansion, talent education, and high-quality development of listed companies.

同时，大会通过沙利文视频号、头豹视频号、经观、微博健康、Choice数据、孔雀开会、天风国际、同花顺iFinD、捷利交易宝、富途、雪球、价值在线、鲸平台、药咖会、机械工业出版社视频号等平台线上同步播出。

The Summit was also livestreamed across platforms including Frost & Sullivan WeChat Channel, LeadLeo Video Channel, The Economic Observer, Weibo Health, Choice Data, Peacock Meeting, TF International Securities, iFinD (Hithink RoyalFlush), Jieli TradePro, Futu, Xueqiu, ValueOnline, Whale Platform, Pharma Cafe, and China Machine Press Video Channel.

首日的大会群英荟萃，星光熠熠，在数百位与会嘉宾的参与下顺利收官，来自机构、企业、高校的嘉宾们为线上线下的观众共同呈现了一场酣畅淋漓、别开生面的智慧盛宴。8月5日，AI时代下人才培养体系——以行业研究为赛道的产教融合实践、AI的进阶与飞跃、生命科学新投资高峰论坛（平行会）——生物医药、生命科学新投资高峰论坛（平行会）——器械专场、生命科学新投资高峰论坛（平行会）——健康科技专场、上市公司高质量发展论坛顺利召开。

The first day of the Summit concluded successfully with hundreds of distinguished guests from institutions, enterprises and universities presenting an inspiring intellectual feast for online and offline audiences. On August 5, the AI-era Talent Development Forum (Industry-Research Integration Practice Focused on Industry Research), Advancement and Leap of AI Forum, and three parallel sessions of the Life Science New Investment Summit — Biopharma, Medical Devices, and Health Tech — as well as the High-Quality Development of Listed Companies Forum, were held as scheduled.

8月5日，2026沙利文峰会——“AI 的进阶与飞跃”分论坛全方位、全链条呈现了2026 年人工智能技术迭代、产业落地与商业变现的阶段性成果。

On August 5, the "Advancement and Leap of AI" sub-forum of the 2026 Frost & Sullivan Summit presented phased achievements in AI technology iteration, industrial implementation and commercial monetization in 2026 across the entire value chain.

论坛上午场聚焦 AI 产业底层核心领域，围绕人工智能安全治理、年度十大技术趋势、AI 芯片商业化落地、具身智能产业化、人机共生机器人研发、决策智能产业价值、多模态大模型重构产业工作流等前沿议题。中国网络空间安全协会副理事长卢卫解读 AI安全治理体系建设成果；腾讯云陈峥、机器科学田野、杉数科技王曦、阶跃星辰李璟、树根互联孙佰贵、智象科技王科、本原数智李逆勇等行业嘉宾，分别围绕具身智能、决策智能、多模态大模型及工业 AI 应用等方向，展示最新实践成果与产业价值。

The morning session focused on core foundational areas of the AI industry, covering cutting-edge topics including AI security governance, annual top 10 technology trends, commercial implementation of AI chips, industrialization of embodied intelligence, R&D of human-robot symbiotic systems, industrial value of decision intelligence, and multimodal large models reshaping industrial workflows. Lu Wei, Vice President of the Cybersecurity Association of China, analyzed the achievements of AI security governance system development. Industry speakers including Jeremy Chen from Tencent Cloud, Tian Ye from RoboScience, Wang Xi from Cardinal Operations (Shanghai) Co., Ltd., Li Jing from StepFun, Sun Baigui from Irootech Technology Co., Ltd., Wang Ke from Zhixiang Technology, and Li Niyong from Benyuan Shuzhi shared the latest practical achievements and industrial value in embodied intelligence, decision intelligence, multimodal large models and industrial AI applications.

下午场聚焦 AI 前沿技术创新、AI Native 产品创新与产业商业化实践，围绕脑机接口技术跃迁、AI Native 产品体系构建、可编程 RNA 设计、AI 企业赴港上市估值逻辑等热点方向完成交流。

The afternoon session focused on cutting-edge AI technology innovation, AI-native product innovation, and industrial commercialization practices, covering hot topics including brain-computer interface technology leaps, AI Native product system building, programmable RNA design, and valuation logic for AI enterprises listing in Hong Kong.

其中，腾讯爆款产品 WorkBuddy 产品负责人围绕从 0 到 1 打造 AI Native 产品背后的组织思考，解析 AI 原生产品在组织协同、产品设计与商业落地等方面的实践路径，为企业推进 AI Native 产品创新提供了参考范本。论坛现场集中发布多项重磅研究成果，包括《全球脑机接口产业发展白皮书（2026）》、《2026 年中国 AI 进阶与飞跃白皮书》、《决策智能：重塑产业经济的 “AI 第三极”》、《具身传感器：智能机器人的感知基座》、《全球具身智能技术创新与应用白皮书》及《2026 年中国 AI 环境下的营销最佳应用实践》，系统梳理并呈现人工智能技术演进、决策智能、具身智能、机器人感知及 AI 营销应用等领域的最新研究成果与发展趋势，为产业创新、技术落地和商业实践提供重要参考依据。

Notably, the product lead of Tencent's hit product WorkBuddy shared organizational insights behind building AI Native products from 0 to 1, analyzing practical paths of AI native products in organizational collaboration, product design and commercial implementation, providing a reference model for enterprises advancing AI Native product innovation. The forum saw the release of multiple major research outcomes, including the Global Brain-Computer Interface Industry Development White Paper（2026）, 2026 China AI Advancement and Leap White Paper, Decision Intelligence: Reshaping the Industrial Economy as the "Third Pole of AI", Embodied Sensors: The Perception Foundation of Intelligent Robots, Global Embodied AI Technology Innovation and Application White Paper, 2026 Best Application Practices for Marketing in an AI Environment, & 2026 China AI Agent Best Practice Rankings, systematically outlining the latest research and development trends in AI technology evolution, decision intelligence, embodied intelligence, robot perception and AI marketing applications, providing important reference for industrial innovation, technology implementation and commercial practice.

同时《2026 年中国 AI Agent（智能体）最佳应用实践榜单》也完成正式发布。榜单围绕技术创新能力、场景落地成效、商业应用价值及行业示范意义等维度，完成对中国 AI Agent 领域代表性优秀产品与应用实践的系统性评选，集中展示智能体领域落地成果与标杆案例，为产业智能化升级和 AI Agent 规模化应用落地提供了可落地的实践参考。两场圆桌对话也分别围绕中美 AI 产业竞争背景下国产 AI 技术突围路径，以及 AI 商业价值释放的商业化路径与实践经验展开深度探讨，完整覆盖 AI 技术、产业、资本与治理等多个维度，全面展现了中国 AI 产业的进阶成果与未来发展潜力。

The 2026 China AI Agent Best Practice Rankings was also officially released. Evaluated across dimensions including technological innovation capability, scenario implementation results, commercial application value and industry demonstration significance, the list systematically selected outstanding representative products and application practices in China's AI Agent sector, showcasing implementation achievements and benchmark cases, and providing actionable practical reference for industrial intelligent upgrading and large-scale AI Agent application. Two panel discussions provided an in-depth exploration of domestic AI technology breakthrough paths amid China-US AI industry competition, and commercialization paths and practical experience for unlocking AI business value, fully covering AI technology, industry, capital and governance, and comprehensively demonstrating the advancements and future development potential of China's AI industry.

本场论坛由中国肝炎防治基金会理事长王宇教授、华龛生物联合创始人刘伟博士分时段主持，聚焦创新药研发突破、技术迭代、国际化布局与资本投资逻辑，汇聚产业龙头、科研机构、投行资本、行业专家深度研讨。香港交易所副总裁姜嘉莉解读港股资本市场对生物医药企业的扶持政策与上市机遇；上海市生物医药行业协会陈少雄教授复盘上海及全国生物医药产业高质量发展整体态势；恒瑞医药张连山博士分享头部药企创新研发体系搭建与全球化布局实战策略。

This session was moderated in turn by Prof. Wang Yu, Chairman, Chinese Foundation for Hepatitis Prevention and Control, and Dr. Liu Wei, Co-founder of Hysigel Biotechnology. Focused on innovative drug R&D breakthroughs, technology iteration, global footprint and capital investment logic, the session gathered industry leaders, research institutions, investment banks and industry experts for in-depth discussion. Jacqueline Jiang, Vice President, HKEX, detailed support policies and listing opportunities for biopharma enterprises in the Hong Kong capital market; Prof. Chen Shaoxiong, Executive President & Secretary-General, Shanghai Biopharmaceutics Industry Association reviewed the high-quality development landscape of biopharma industry in Shanghai and nationwide; Dr. Zhang Lianshan,Executive Vice President & Director, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) shared practical strategies for leading pharma enterprises to build innovative R&D systems and global footprint.

论坛现场正式发布《2026中国生物医药国际化发展蓝皮书》《2026全球基因疗法行业发展蓝皮书》两份权威报告。威斯津生物、华龛生物、汉鼎医药、元思生肽等企业代表，分别分享了CAR-T细胞治疗、3D细胞智造、PDC新药研发、AI赋能多肽药物研发等前沿成果。两场圆桌对话围绕"中国创新药全球生态共建""AI赋能生物医药研发革新"展开深度交流，汇聚摩根士丹利、中信证券、德睿智药、腾迈医药等机构代表，全面复盘中国生物医药产业创新成果，精准解读国际化发展路径与资本投资机遇。

The forum officially released two authoritative reports: China Biopharma International Development Blue Book (2026) and Global Gene Therapy Industry Development Blue Book (2026). Representatives from enterprises including WestGene Biopharma, Hysigel Biotechnology, Handing Pharmaceuticals, and Syneron Bio shared cutting-edge achievements in CAR-T cell therapy, 3D cell intelligent manufacturing, PDC new drug R&D, and AI-empowered peptide drug R&D. Two panel discussion featured in-depth exchanges on "co-building global ecosystem for Chinese innovative drugs" and "AI-empowered biopharma R&D innovation", gathering representatives from Morgan Stanley, CITIC Securities, MindRank, and TandemAI, comprehensively reviewing innovation achievements of China's biopharma industry, and accurately interpreting globalization development paths and capital investment opportunities.

2026沙利文峰会——"创新无界，器械有为"生命科学新投资高峰论坛平行会医疗器械专场顺利举行，由普华永道中国合伙人袁成飞主持，沙利文中国高级合伙人兼董事总经理毛化致开场辞。上午场，东软医疗、星桥资本、虚之实、魅丽纬叶分别就高端医疗设备与AI融合、行业投融资全景、非侵入式脑机接口、微创介入与慢病管理作主题分享；随后的圆桌由中金公司汪寅彦主持，诺令生物毛雯博士、涛影医疗蔡宗远博士与生命盾医疗、明视脑机、比邻星创投等嘉宾，围绕"从临床创新突破到全球拓展"探讨技术转化与出海节奏。

At the 2026 Frost & Sullivan Summit, the "Innovation Without Bounds, Device Leadership" medical device parallel session of the Life Science New Investment Summit was successfully held, moderated by Yuan Chengfei, Partner, Tax and Business Consulting Department, PwC China, Shanghai Office, with opening remarks by Fred Mao, Senior Partner & Managing Director of Frost & Sullivan China. In the morning session, Neusoft Medical, Bridges Capital, Hangzhou Neureal Technology Co., Ltd., and BRATTEA delivered keynotes on the integration of high-end medical devices and AI, industry investment and financing landscape, non-invasive brain-computer interfaces, and minimally invasive intervention and chronic disease management. The following panel, moderated by Wang Yinyan, Executive Director, CICC, gathered Dr. Mao Wen, Chairman of the board & CEO, Nanjing Novlead Biotechnology Co., Ltd., Dr.Tsai Tsung-yuan, CEO, Shanghai TAOiMAGE Medical Tech.Co.,Ltd, and representatives from Lifeshield Medical, Mindtrix Technology Co., Ltd., and Proxima Capital, discussing technology translation and global expansion pace under the theme "From Clinical Innovation Breakthrough to Global Expansion".

下午场以康德生物梅敏飞的"癌症早检与保险报销体系"开篇，图湃医疗、影禾医脉、艾科脉医疗、鼎科医疗、诺源医疗、华硼中子依次分享眼科设备、医学影像AGI、心脏电生理、后集采破局、荧光导航手术与BNCT的一线进展；压轴圆桌由广发证券李映文主持，华科先锋、纳米维景、阶梯医疗、汉诺医疗、百洋众信基金共议器械创新合作模式。

The afternoon session opened with a presentation by Mei Minfei, Strategy Director, KANTE (Shenzhen) Biotechnology Co., Ltd. on "early cancer detection and insurance reimbursement systems", followed by presentations on frontline progress by TowardPi (Beijing) Medical Technology Ltd., Shanghai Medical Image Insights Intelligent Technology Co., Ltd., AccuPulse Medical Device (Zhejiang) Ltd., DK Medical Technology, Nanjing Nuoyuan Medical Device Co., Ltd., and HBNCT Technology (Hangzhou) Co., Ltd. on ophthalmic devices, medical imaging AGI, cardiac electrophysiology, breakthroughs in the post-centralized procurement era, fluorescence-guided surgery and BNCT. The closing panel, moderated by Li Yingwen, General Manager of the Healthcare Industry Group, Investment Banking Division, GF Securities Moderator, gathered Huake Pioneer, Nanovision Technology Group, Shanghai StairMed Medical Technology Co., Ltd, Lifemotion Medical Technology Co., Ltd., and Baheal Zhongxin Capital to discuss device innovation cooperation models.

论坛同期发布《全球脑机接口产业发展白皮书》《2026全球数智医学影像生态行业发展蓝皮书》。

Concurrently, the forum released he Global Brain-Computer Interface Industry Development White Paper and Global Digital & Intelligent Medical Imaging Ecosystem Industry Development Blue Book (2026).

生命科学新投资高峰论坛平行会——健康科技专场

Life Science New Investment Summit Parallel Session: Health Tech

该分论坛由沙利文、捷利交易宝、云科技、金洲控股、国枫律师事务所联合主办，中国上市公司协会境外分会提供支持。论坛基于AI技术革命与资本市场改革双重背景，聚焦上市公司高质量发展、资本运作、全球化布局及合规风控等核心议题。中国上市公司协会明确上市公司是培育新质生产力的核心载体；香港交易所分享港股市场改革新动向；云知声、翼菲科技、楚航科技、优必选等科创企业展示AI落地与产业升级成果；国枫律师事务所、金洲控股、蚂蚁数科、达力普控股等机构就海外并购风控、港股投资策略、出海实践等话题贡献专业洞见。

This sub-forum was co-hosted by Frost & Sullivan, TradeGo FinTech Limited, Cloud Technology, Golden Continent Holdings Limited, and Grandway Law Offices, with support from the Overseas Chapter of the China Association for Public Companies. Against the dual backdrop of AI technology revolution and capital market reform, the forum focused on core topics including high-quality development of listed companies, capital operation, global layout and compliance risk control. China Association for Public Companies clarified that listed companies are the core vehicles for cultivating new quality productive forces; Hong Kong Stock Exchange shared new trends of Hong Kong market reform; sci-tech enterprises including Unisound AI Technology, Robotphoenix Intelligent Technology, Nanjing Chuhang Technology Co., Ltd., and UBTech Robotics showcased achievements in AI implementation and industrial upgrading; Grandway Law Offices, Golden Continent Holdings Limited, Ant Digital Technologies, and Dalipal Holdings Limited contributed professional insights on risk control in overseas M&A, Hong Kong stock investment strategies, and global expansion practice.

全天13场主题演讲与2场圆桌对话，搭建起监管机构、交易所、上市公司及专业服务机构间的高效交流平台，为中国企业在全球竞争中把握变革机遇提供了务实的前瞻指引。

Featuring 13 keynote speeches and 2 panel discussions throughout the day, the forum built an efficient exchange platform among regulators, exchanges, listed companies and professional service institutions, providing practical forward-looking guidance for Chinese enterprises to seize transformation opportunities in global competition.

至此，第二十届沙利文全球增长、科创与领导力峰会暨第五届新投资大会圆满闭幕。

With this, the 20th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 5th New Investment Event successfully concluded.

沙利文全球合伙人兼大中华区董事长王昕博士表示：沙利文的使命是向世界传递中国的增长、科创与领导力，让世界更清晰地看懂中国的价值，也让中国加速拥抱世界的机遇。沙利文峰会在全球有30多年历史，在中国连续成功举办20届，风雨无阻。未来将延续大会立足上海、服务中国、面向全球、合作共赢的承诺，帮助企业实现国内与出海增长战略，通过科创赋能产业转型升级，培育富有领导力的中国企业家，最终促进中国经济社会高质量发展！”

Dr. Neil Wang, Global Senior VP, Co-Chairman of Asia Pacific, and Chairman of China, Frost & Sullivan, stated: "Frost & Sullivan's mission is to communicate China's growth, innovation and leadership to the world, helping the world clearly understand China's value, and helping China embrace global opportunities faster. The Frost & Sullivan Summit has a history of over 30 years globally, and has been successfully held for 20 consecutive years in China, rain or shine. Going forward, we will uphold our commitment of being based in Shanghai, serving China, and remaining globally oriented, and pursuing win-win cooperation, helping enterprises achieve domestic and global growth strategies, empowering industrial transformation and upgrading through sci-tech innovation, cultivating leadership among Chinese entrepreneurs, and ultimately promoting high-quality economic and social development in China."

沙利文将持续与各方机构一起协力共行，帮助企业加速成长步伐，助力企业在行业内取得增长、科创、领先的标杆地位，与所有合作伙伴一起，锚定创新爆发期，共塑转型增长新未来。

Frost & Sullivan will continue to work with all partner institutions to accelerate enterprise growth, help enterprises achieve benchmark positions in growth, innovation and leadership in their industries, and together with all partners, capitalize on the boom in innovation and shape a new future of transformational growth.

我们明年再相聚！

See you next year!